Cemiplimab for Advanced Adrenocortical Cancer

We are studying whether cemiplimab can help patients with advanced adrenocortical cancer maintain their health after initial treatment. This trial focuses on those who have not experienced disease progression.

>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOralInjectionOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Libtayo
Libtayo is a cancer medicine that helps the immune system find and fight certain advanced skin and lung cancers.
Lysodren
Lysodren is a medicine used to treat cancer of the adrenal gland.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Cemiplimab
Cemiplimab is a substance that helps the immune system find and attack certain cancers by blocking a protein that suppresses immune cells.
Mitotane
Mitotane is a substance that destroys adrenal gland tissue to treat adrenal cancer and reduce excess cortisol production.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
Dipartimento oncologico - Comprehensive Cancer Center
Brescia, Italy
Sponsor: Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.